Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02980705 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of SUNPG1622
A Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
- Terminated
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT02980705 is a Phase 2 study that was terminated before completion, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 180 participants.
The verdict
NCT02980705, a Phase 2 study, was terminated before completion, sponsored by Sun Pharmaceutical Industries Limited.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.
Interventions
- DRUG Placebo dose
- DRUG SUNPG1622 I dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2017-11-06 |
| Est. Completion | 2019-09-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02980705
The ClinicalTrials.gov registry entry for NCT02980705 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo dose is the first listed.
NCT02980705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02980705 about?
NCT02980705 is a clinical study titled "Efficacy and Safety Study of SUNPG1622". This is a randomized, double-Blind, placebo-controlled Phase 2a study to evaluate the efficacy and safety of SUNPG1622.
What is the current status of trial NCT02980705?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2017-11-06. Estimated completion is 2019-09-03.
What interventions are being tested in trial NCT02980705?
The interventions under investigation include: Placebo dose (DRUG), SUNPG1622 I dose (DRUG).
Who is sponsoring clinical trial NCT02980705?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.